Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 9
Submit an article Journal homepage
456
Views
2
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics of Antiangiogenic and Antineovascular Therapies of Age-Related Macular Degeneration

Elisa Agosta1 Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55-56125, Pisa, ItalyView further author information
,
Stefano Lazzeri2 Ophthalmology Unit, University of Pisa, Pisa, ItalyView further author information
,
Paola Orlandi1 Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55-56125, Pisa, ItalyView further author information
,
Michele Figus2 Ophthalmology Unit, University of Pisa, Pisa, ItalyView further author information
,
Anna Fioravanti1 Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55-56125, Pisa, ItalyView further author information
,
Teresa Di Desidero1 Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55-56125, Pisa, ItalyView further author information
,
Maria Sole Sartini2 Ophthalmology Unit, University of Pisa, Pisa, ItalyView further author information
,
Marco Nardi2 Ophthalmology Unit, University of Pisa, Pisa, ItalyView further author information
,
Romano Danesi1 Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55-56125, Pisa, ItalyView further author information
&
Guido Bocci1 Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55-56125, Pisa, ItalyCorrespondence[email protected]
View further author information
 show all
Pages 1037-1053 | Published online: 27 Jul 2012

References

  • Friedman DS , O‘ColmainBJ, MunozB et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4) , 564–572 (2004).
  • Montezuma SR , SobrinL, SeddonJM. Review of genetics in age related macular degeneration. Semin. Ophthalmol.22(4) , 229–240 (2007).
  • Jager RD , MielerWF, MillerJW. Age-related macular degeneration. N. Engl. J. Med.358(24) , 2606–2617 (2008).
  • de Jong PT . Age-related macular degeneration. N. Engl. J. Med.355(14) , 1474–1485 (2006).
  • Kvanta A , AlgverePV, BerglinL et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37(9) , 1929–1934 (1996).
  • Witmer AN , VrensenGF, Van Noorden CJ et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res.22(1) , 1–29 (2003).
  • Frank RN . Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. Ophthalmic Res.29(5) , 341–353 (1997).
  • Pasqualetti G , DanesiR, Del Tacca M et al. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics8(1) , 49–66 (2007).
  • Bhisitkul RB . Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol.90(12) , 1542–1547 (2006).
  • Rakic JM , LambertV, DevyL et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44(7) , 3186–3193 (2003).
  • Soker S , TakashimaS, MiaoHQ et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(6) , 735–745 (1998).
  • Keyt BA , BerleauLT, NguyenHV et al. The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271(13) , 7788–7795 (1996).
  • Konopatskaya O , ChurchillAJ, HarperSJ et al. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis. 12 , 626–632 (2006).
  • Perrin RM , KonopatskayaO, QiuY et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48(11) , 2422–2427 (2005).
  • Kliffen M , SharmaHS, MooyCM et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 81(2) , 154–162 (1997).
  • Churchill AJ , CarterJG, LovellHC et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum. Mol. Genet.15(19) , 2955–2961 (2006).
  • Boekhoorn SS , IsaacsA, UitterlindenAG et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology 115(11) , 1899–1903 (2008).
  • Janik-Papis K , ZarasM, KrzyzanowskaA et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp. Mol. Pathol. 87(3) , 234–238 (2009).
  • Lin JM , WanL, TsaiYY et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am. J. Ophthalmol. 145(6) , 1045–1051 (2008).
  • Shalaby F , RossantJ, YamaguchiTP et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535) , 62–66 (1995).
  • Fang AM , LeeAY, KulkarniM et al. Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol. Vis. 15 , 2710–2719 (2009).
  • Galan A , FerlinA, CarettiL et al. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 117(9) , 1769–1774 (2010).
  • Klein RJ , ZeissC, ChewEY et al. Complement factor H polymorphism in age-related macular degeneration. Science 308(5720) , 385–389 (2005).
  • Edwards AO , RitterR 3rd, Abel KJ et al. Complement factor H polymorphism and age-related macular degeneration. Science308(5720) , 421–424 (2005).
  • Hageman GS , AndersonDH, JohnsonLV et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad. Sci. USA 102(20) , 7227–7232 (2005).
  • Haines JL , HauserMA, SchmidtS et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720) , 419–421 (2005).
  • Johnson LV , LeitnerWP, StaplesMK et al. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp. Eye Res. 73(6) , 887–896 (2001).
  • Scholl HP , Charbel Issa P, Walier M et al. Systemic complement activation in age-related macular degeneration. PLoS ONE3(7) , E2593 (2008).
  • Sivaprasad S , ChongNV. The complement system and age-related macular degeneration. Eye (Lond.)20(8) , 867–872 (2006).
  • Majewski J , SchultzDW, WeleberRG et al. Age-related macular degeneration – a genome scan in extended families. Am. J. Hum. Genet. 73(3) , 540–550 (2003).
  • Seddon JM , SantangeloSL, BookK et al. A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. Am. J. Hum. Genet. 73(4) , 780–790 (2003).
  • Iyengar SK , SongD, KleinBE et al. Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am. J. Hum. Genet. 74(1) , 20–39 (2004).
  • Kenealy SJ , SchmidtS, AgarwalA et al. Linkage analysis for age-related macular degeneration supports a gene on chromosome 10.26. Mol. Vis. 10 , 57–61 (2004).
  • Weeks DE , ConleyYP, TsaiHJ et al. Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10.26, and 17q25 regions. Am. J. Hum. Genet. 75(2) , 174–189 (2004).
  • Seddon JM , GenslerG, RosnerB. C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology117(8) , 1560–1566 (2010).
  • Rivera A , FisherSA, FritscheLG et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum. Mol. Genet. 14(21) , 3227–3236 (2005).
  • Fritsche LG , LoenhardtT, JanssenA et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat. Genet. 40(7) , 892–896 (2008).
  • Kanda A , ChenW, OthmanM et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc. Natl Acad. Sci. USA 104(41) , 16227–16232 (2007).
  • Wang G , SpencerKL, CourtBL et al. Localization of age-related macular degeneration-associated ARMS2 in cytosol, not mitochondria. Invest. Ophthalmol. Vis. Sci. 50(7) , 3084–3090 (2009).
  • Kortvely E , HauckSM, DuetschG et al. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest. Ophthalmol. Vis. Sci. 51(1) , 79–88 (2010).
  • Tong Y , LiaoJ, ZhangY et al. LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: a HuGE review and meta-analysis. Mol. Vis.16 , 1958–1981 (2010).
  • Tocharus J , TsuchiyaA, KajikawaM et al. Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-β signaling. Dev. Growth Differ. 46(3) , 257–274 (2004).
  • Miyake K , HorikawaY, HaraK et al. Association of TCF7L2 polymorphisms with susceptibility to Type 2 diabetes in 4,087 Japanese subjects. J. Hum. Genet. 53(2) , 174–180 (2008).
  • Ly DH , LockhartDJ, LernerRA et al. Mitotic misregulation and human aging. Science 287(5462) , 2486–2492 (2000).
  • Grau S , RichardsPJ, KerrB et al. The role of human HtrA1 in arthritic disease. J. Biol. Chem. 281(10) , 6124–6129 (2006).
  • Oka C , TsujimotoR, KajikawaM et al. HtrA1 serine protease inhibits signaling mediated by Tgfβ family proteins. Development 131(5) , 1041–1053 (2004).
  • Dewan A , LiuM, HartmanS et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science314(5801) , 989–992 (2006).
  • Yang Z , CampNJ, SunH et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314(5801) , 992–993 (2006).
  • Francis PJ , AppukuttanB, SimmonsE et al. Rhesus monkeys and humans share common susceptibility genes for age-related macular disease. Hum. Mol. Genet. 17(17) , 2673–2680 (2008).
  • Kaur I , KattaS, HussainA et al. Variants in the 10.26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients. Invest. Ophthalmol. Vis. Sci. 49(5) , 1771–1776 (2008).
  • Deangelis MM , JiF, AdamsS et al. Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration. Ophthalmology 115(7) , 1209–1215.E7 (2008).
  • Hughes AE , OrrN, PattersonC et al. Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking. PLoS Med. 4(12) , E355 (2007).
  • Lu F , HuJ, ZhaoP et al. HTRA1 variant increases risk to neovascular age-related macular degeneration in Chinese population. Vision Res.47(24) , 3120–3123 (2007).
  • Yoshida T , DeWanA, ZhangH et al. HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration. Mol. Vis.13 , 545–548 (2007).
  • Mahley RW . Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science240(4852) , 622–630 (1988).
  • Anderson DH , MullinsRF, HagemanGS et al. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134(3) , 411–431 (2002).
  • Dithmar S , ShararaNA, CurcioCA et al. Murine high-fat diet and laser photochemical model of basal deposits in Bruch membrane. Arch. Ophthalmol. 119(11) , 1643–1649 (2001).
  • Ong JM , ZorapapelNC, RichKA et al. Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice. Invest. Ophthalmol. Vis. Sci. 42(8) , 1891–1900 (2001).
  • Simonelli F , MargaglioneM, TestaF et al. Apolipoprotein E polymorphisms in age-related macular degeneration in an Italian population. Ophthalmic Res. 33(6) , 325–328 (2001).
  • Schmidt S , KlaverC, SaundersA et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genet. 23(4) , 209–223 (2002).
  • Zareparsi S , ReddickAC, BranhamKE et al. Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. Invest. Ophthalmol. Vis. Sci. 45(5) , 1306–1310 (2004).
  • McKay GJ , PattersonCC, ChakravarthyU et al. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. Hum. Mutat. 32(12) , 1407–1416 (2011).
  • Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol.131(5) , 541–560 (2001).
  • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalmol.117(10) , 1329–1345 (1999).
  • Prasad PS , SchwartzSD, HubschmanJP. Age-related macular degeneration: current and novel therapies. Maturitas66(1) , 46–50 (2010).
  • Salam A , MathewR, SivaprasadS. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol.89(5) , 405–411 (2011).
  • Waheed NK , MillerJW. Aptamers, intramers, and vascular endothelial growth factor. Int. Ophthalmol. Clin.44(3) , 11–22 (2004).
  • Gragoudas ES , AdamisAP, CunninghamET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med.351(27) , 2805–2816 (2004).
  • D‘Amico DJ , MasonsonHN, PatelM et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6) , 992–1001.E6 (2006).
  • Avery RL , PieramiciDJ, RabenaMD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3) , 363–372.E5 (2006).
  • Spaide RF , LaudK, FineHF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26(4) , 383–390 (2006).
  • Arevalo JF , Fromow-GuerraJ, SanchezJG et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American collaborative retina study group at 12 months follow-up. Retina 28(10) , 1387–1394 (2008).
  • Wu L , Martinez-CastellanosMA, Quiroz-MercadoH et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American collaborative retina study group (PACORES). Graefes. Arch. Clin. Exp. Ophthalmol. 246(1) , 81–87 (2008).
  • Patel PJ , BunceC, TufailA. A randomised, double-masked Phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared with standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials9 , 56 (2008).
  • Tufail A , PatelPJ, EganC et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 340 , C2459 (2010).
  • Martin DF , MaguireMG, YingGS et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20) , 1897–1908 (2011).
  • Polak MB , Behar-CohenF. Exudative age-related macular degeneration: efficacy and limits of the different treatments. J. Fr. Ophtalmol.31(5) , 537–556 (2008).
  • Mordenti J , CuthbertsonRA, FerraraN et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol. 27(5) , 536–544 (1999).
  • Ferrara N , GerberHP, LeCouterJ. The biology of VEGF and its receptors. Nat. Med.9(6) , 669–676 (2003).
  • Rosenfeld PJ , SchwartzSD, BlumenkranzMS et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112(6) , 1048–1053 (2005).
  • Steinbrook R . The price of sight – ranibizumab, bevacizumab, and the treatment of macular degeneration. N. Engl. J. Med.355(14) , 1409–1412 (2006).
  • Folk JC , StoneEM. Ranibizumab therapy for neovascular age-related macular degeneration. N. Engl. J. Med.363(17) , 1648–1655 (2010).
  • Rosenfeld PJ , BrownDM, HeierJS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14) , 1419–1431 (2006).
  • Brown DM , KaiserPK, MichelsM et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14) , 1432–1444 (2006).
  • Brown DM , MichelsM, KaiserPK et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1) , 57–65.E5 (2009).
  • Abraham P , YueH, WilsonL. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am. J. Ophthalmol.150(3) , 315–324.E1 (2010).
  • Schmidt-Erfurth U , EldemB, GuymerR et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118(5) , 831–839 (2011).
  • Lalwani GA , RosenfeldPJ, FungAE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am. J. Ophthalmol. 148(1) , 43–58.E1 (2009).
  • Holz FG , AmoakuW, DonateJ et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118(4) , 663–671 (2011).
  • Curtis LH , HammillBG, QuallsLG et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am. J. Ophthalmol. 153(6) , 1116–1124.e1 (2012).
  • Wolf CR , SmithG, SmithRL. Science, medicine, and the future: pharmacogenetics. BMJ320(7240) , 987–990 (2000).
  • Parmeggiani F , GemmatiD, CostagliolaC et al. Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Recent Pat. DNA Gene Seq. 3(2) , 114–122 (2009).
  • Parmeggiani F , CostagliolaC, GemmatiD et al. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenet. Genomics 17(12) , 1039–1046 (2007).
  • Parmeggiani F , GemmatiD, CostagliolaC et al. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Pharmacogenomics 10(1) , 81–95 (2009).
  • Parmeggiani F , CostagliolaC, GemmatiD et al. Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49(7) , 3100–3106 (2008).
  • Chowers I , MeirT, LedermanM et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol. Vis. 14 , 2263–2271 (2008).
  • Chowers I , CohenY, Goldenberg-CohenN et al. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel. Mol. Vis. 14 , 1829–1834 (2008).
  • Goverdhan SV , HannanS, NewsomRB et al. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye (Lond.) 22(6) , 849–854 (2008).
  • Seitsonen SP , JarvelaIE, MeriS et al. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur. J. Ophthalmol. 17(6) , 943–949 (2007).
  • Brantley MA Jr, Edelstein SL, King JM et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye (Lond.)23(3) , 626–631 (2009).
  • Feng X , XiaoJ, LongvilleB et al. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 116(10) , 1908–1912.E1 (2009).
  • Tsuchihashi T , MoriK, Horie-InoueK et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 118(1) , 93–100 (2011).
  • Immonen I , SeitsonenS, TommilaP et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 117(1) , 103–108 (2010).
  • Brantley MA Jr, Fang AM, King JM et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology114(12) , 2168–2173 (2007).
  • Nischler C , OberkoflerH, OrtnerC et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol. 89(4) , E344–E349 (2010).
  • Nakata I , YamashiroK, NakanishiH et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J. Ophthalmol.55(5) , 435–443 (2011).
  • Imai D , MoriK, Horie-InoueK et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J. Ocul. Biol. Dis. Infor.3(2) , 53–59 (2010).
  • Lee AY , RayaAK, KymesSM et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br. J. Ophthalmol. 93(5) , 610–613 (2009).
  • Teper SJ , NowinskaA, PilatJ et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol. Vis. 16 , 2598–2604 (2010).
  • Kloeckener-Gruissem B , BarthelmesD, LabsS et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 52(7) , 4694–4702 (2011).
  • Wickremasinghe SS , XieJ, LimJ et al. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest. Ophthalmol. Vis. Sci. 52(7) , 4072–4079 (2011).
  • McKibbin M , AliM, BansalS et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br. J. Ophthalmol.96(2) , 208–212 (2012).
  • Bocci G , LoupakisF. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics12(8) , 1077–1080 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.